ERBB2 and breast carcinoma: (23) showed that as a pan-cancer predictive biomarker for HER2-targeted therapy, the HER2 index, combined with HER2 multi-omics capabilities, can help identify potential candidates for such therapy in multiple tumor types, including breast cancer.